Monte Rosa Therapeutics, Inc. (GLUE) has 10 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 2 sales totalling $1.4M. Most recent filing: July 17, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| July 17, 2026 filed July 16, 2026 | Warmuth Markus President & CEO | −$220,219 | 9,500 | −2% | No | |
|
|
||||||
| July 16, 2026 filed July 15, 2026 | Champoux Jennifer Chief Operating Officer | $84,413 | 13,053 | 0% | Yes | |
|
|
||||||
| July 7, 2026 filed July 6, 2026 | Townson Sharon Chief Scientific Officer | $103,009 | 18,000 | 0% | Yes | |
|
|
||||||
| July 6, 2026 filed July 1, 2026 | Behbahani Ali Director | $0 | 1,030,000 | −100% | No | |
|
|
||||||
| July 1, 2026 filed June 30, 2026 | Janku Filip Chief Medical Officer | $59,964 | 16,221 | 0% | Yes | |
|
|
||||||
Showing the 5 most recent of 10 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free